147.86
price down icon0.85%   -1.27
pre-market  시장 영업 전:  146.05   -1.81   -1.22%
loading
전일 마감가:
$149.13
열려 있는:
$148.82
하루 거래량:
2.45M
Relative Volume:
1.50
시가총액:
$21.68B
수익:
$9.61B
순이익/손실:
$1.53B
주가수익비율:
14.15
EPS:
10.453
순현금흐름:
$1.85B
1주 성능:
+0.09%
1개월 성능:
+6.74%
6개월 성능:
+23.04%
1년 성능:
-19.41%
1일 변동 폭
Value
$147.54
$149.91
1주일 범위
Value
$147.54
$151.92
52주 변동 폭
Value
$110.03
$185.00

Biogen Inc Stock (BIIB) Company Profile

Name
명칭
Biogen Inc
Name
전화
(781) 464-2000
Name
주소
225 BINNEY STREET, CAMBRIDGE, MA
Name
직원
7,605
Name
트위터
@biogen
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
BIIB's Discussions on Twitter

BIIB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
BIIB
Biogen Inc
147.86 21.86B 9.61B 1.53B 1.85B 10.45
Drug Manufacturers - General icon
LLY
Lilly Eli Co
813.53 735.18B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.60 450.37B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
225.14 401.96B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
121.80 238.94B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.58 217.38B 63.43B 16.42B 14.72B 6.4861

Biogen Inc Stock (BIIB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-09-25 개시 Jefferies Buy
2025-07-21 재개 Truist Hold
2025-04-28 다운그레이드 HSBC Securities Buy → Hold
2025-04-04 다운그레이드 Argus Buy → Hold
2025-02-11 개시 Bernstein Mkt Perform
2025-01-02 다운그레이드 Piper Sandler Overweight → Neutral
2024-12-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2024-12-16 다운그레이드 Stifel Buy → Hold
2024-12-10 재개 BofA Securities Neutral
2024-12-09 다운그레이드 Jefferies Buy → Hold
2024-11-18 다운그레이드 Needham Buy → Hold
2024-11-15 개시 Wolfe Research Peer Perform
2024-11-14 개시 Citigroup Neutral
2024-10-31 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-10-10 재개 Raymond James Mkt Perform
2024-02-14 재확인 Needham Buy
2024-02-14 다운그레이드 Wells Fargo Overweight → Equal Weight
2024-01-24 다운그레이드 UBS Buy → Neutral
2023-12-20 재개 Cantor Fitzgerald Overweight
2023-12-07 업그레이드 Raymond James Mkt Perform → Outperform
2023-09-06 개시 HSBC Securities Buy
2023-07-27 개시 Scotiabank Sector Outperform
2023-07-24 재확인 UBS Buy
2023-05-01 업그레이드 Guggenheim Neutral → Buy
2023-04-17 업그레이드 Piper Sandler Neutral → Overweight
2022-10-26 업그레이드 Goldman Neutral → Buy
2022-10-13 업그레이드 Stifel Hold → Buy
2022-10-07 업그레이드 Argus Hold → Buy
2022-09-28 업그레이드 BMO Capital Markets Market Perform → Outperform
2022-09-28 업그레이드 Mizuho Neutral → Buy
2022-09-28 업그레이드 Robert W. Baird Neutral → Outperform
2022-04-18 업그레이드 Wells Fargo Equal Weight → Overweight
2022-03-08 다운그레이드 Stifel Buy → Hold
2022-03-03 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2022-02-04 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-02-04 재확인 Barclays Equal Weight
2022-02-04 재확인 BofA Securities Neutral
2022-02-04 재확인 Cowen Outperform
2022-02-04 재확인 Morgan Stanley Overweight
2022-02-04 재확인 Needham Buy
2022-02-04 재확인 Oppenheimer Outperform
2022-02-04 재확인 RBC Capital Mkts Sector Perform
2022-02-04 재확인 Robert W. Baird Neutral
2022-02-04 재확인 Wedbush Neutral
2022-02-04 재확인 Wells Fargo Equal Weight
2022-02-04 재확인 Wolfe Research Peer Perform
2022-01-13 다운그레이드 Guggenheim Buy → Neutral
2022-01-12 다운그레이드 Piper Sandler Overweight → Neutral
2021-12-10 재개 Raymond James Mkt Perform
2021-12-09 재개 Wells Fargo Equal Weight
2021-12-06 개시 Goldman Neutral
2021-11-19 개시 BMO Capital Markets Outperform
2021-09-23 개시 Needham Buy
2021-06-18 업그레이드 Piper Sandler Neutral → Overweight
2021-06-14 재확인 Truist Buy
2021-06-11 업그레이드 Bernstein Mkt Perform → Outperform
2021-06-10 업그레이드 UBS Neutral → Buy
2021-06-08 업그레이드 Atlantic Equities Underweight → Neutral
2021-06-08 재확인 Barclays Equal Weight
2021-06-08 업그레이드 Citigroup Sell → Neutral
2021-06-08 재확인 H.C. Wainwright Buy
2021-06-08 재확인 Jefferies Buy
2021-06-08 재확인 Morgan Stanley Overweight
2021-06-08 재확인 RBC Capital Mkts Sector Perform
2021-06-08 업그레이드 Robert W. Baird Underperform → Neutral
2021-06-08 재확인 Stifel Buy
2021-06-08 업그레이드 William Blair Mkt Perform → Outperform
2021-06-07 업그레이드 BofA Securities Underperform → Neutral
2021-06-07 업그레이드 Cowen Market Perform → Outperform
2021-06-07 업그레이드 Raymond James Underperform → Mkt Perform
2021-02-05 다운그레이드 DZ Bank Buy → Hold
2021-01-29 업그레이드 Stifel Hold → Buy
2020-11-10 업그레이드 DZ Bank Hold → Buy
2020-11-09 다운그레이드 Atlantic Equities Neutral → Underweight
2020-11-09 다운그레이드 BofA Securities Neutral → Underperform
2020-11-09 다운그레이드 Cowen Outperform → Market Perform
2020-11-09 재확인 H.C. Wainwright Buy
2020-11-04 업그레이드 BofA Securities Underperform → Neutral
2020-11-04 업그레이드 Jefferies Hold → Buy
2020-11-04 업그레이드 Wells Fargo Equal Weight → Overweight
2020-10-28 개시 UBS Neutral
2020-07-27 업그레이드 Morgan Stanley Underweight → Overweight
2020-06-22 다운그레이드 Barclays Overweight → Equal Weight
2020-06-22 재확인 RBC Capital Mkts Sector Perform
2020-06-09 다운그레이드 Bernstein Outperform → Mkt Perform
2020-04-23 다운그레이드 Citigroup Neutral → Sell
2020-04-23 다운그레이드 Raymond James Mkt Perform → Underperform
2020-03-31 개시 Wolfe Research Peer Perform
2020-02-27 개시 Barclays Overweight
2020-01-27 업그레이드 Canaccord Genuity Hold → Buy
2019-12-13 업그레이드 Credit Suisse Underperform → Neutral
2019-12-02 다운그레이드 Robert W. Baird Neutral → Underperform
모두보기

Biogen Inc 주식(BIIB)의 최신 뉴스

pulisher
Oct 29, 2025

Analyzing Biogen Inc. with multi timeframe charts2025 Top Gainers & Daily Volume Surge Signals - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Biogen (BIIB): Reassessing Valuation After Recent Share Price Momentum - simplywall.st

Oct 29, 2025
pulisher
Oct 29, 2025

United States Biotechnology Market 2025: Industry - openPR.com

Oct 29, 2025
pulisher
Oct 29, 2025

Why Biogen Inc. (IDP) stock stays on top picksWeekly Investment Summary & Safe Capital Growth Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

PEGylated Proteins Market See Incredible Growth 2025-2032 | Biogen Inc, Pfizer Inc, and UCB S.A. - openPR.com

Oct 29, 2025
pulisher
Oct 29, 2025

Is Biogen Inc. stock a safe buy before earnings2025 Geopolitical Influence & Detailed Earnings Play Alerts - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

United States Biosimilars Market is expected to reach US$ 171.79 - openPR.com

Oct 29, 2025
pulisher
Oct 29, 2025

Nisa Investment Advisors LLC Has $6.39 Million Stock Position in Biogen Inc. $BIIB - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Brighton Jones LLC Purchases New Stake in Biogen Inc. $BIIB - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Is Biogen Inc. stock a top momentum playJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com

Oct 29, 2025
pulisher
Oct 28, 2025

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect - The Globe and Mail

Oct 28, 2025
pulisher
Oct 28, 2025

Biogen Seeks To Stand Out in Lupus With New Anti-CD40L Data - BioSpace

Oct 28, 2025
pulisher
Oct 28, 2025

Will Biogen Inc. (IDP) stock benefit from commodity supercycleJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Volatility clustering patterns for Biogen Inc.Earnings Risk Summary & Fast Entry High Yield Tips - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Biogen Inc. (IDP) stock benefit from sector leadershipJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Sumitomo Mitsui Trust Group Inc. Decreases Stake in Biogen Inc. $BIIB - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Key metrics from Biogen Inc.’s quarterly dataPortfolio Risk Summary & Technical Pattern Alert System - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Biogen Inc.’s volatility index tracking explainedMarket Performance Report & Verified Short-Term Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Historical volatility pattern of Biogen Inc. visualizedLong Setup & Weekly Top Gainers Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

United States Inflammatory Bowel Disease Market is expected - openPR.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Biogen Inc. stock gain from strong economyJuly 2025 Earnings & Fast Gaining Stock Reports - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Institutional scanner results for Biogen Inc.July 2025 Rallies & Technical Analysis for Trade Confirmation - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Biogen Inc. (IDP) stock a buy on weaknessJuly 2025 Sector Moves & Consistent Profit Trade Alerts - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

How to escape a deep drawdown in Biogen Inc.Weekly Loss Report & Daily Chart Pattern Signal Reports - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Felzartamab Trial: A New Hope for Kidney Transplant Patients - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s PMN Study: A Potential Game-Changer for Kidney Disease Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Litifilimab Study: A Promising Step for Lupus Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s New Study on Felzartamab: A Potential Game-Changer for Kidney Transplant Patients - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Study on Diroximel Fumarate: A Closer Look at Pregnancy Outcomes - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Litifilimab Study: A Potential Game-Changer in Lupus Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Nusinersen Study: Exploring Pregnancy Outcomes in SMA Patients - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Innovative Approach in SMA Treatment: ThecaFlex DRx™ System Study Update - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Innovative Approach to SMA Treatment: A Study Update - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s New Study on Omaveloxolone: A Potential Game-Changer for Friedreich’s Ataxia - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s BIIB142 Study: A New Chapter in Drug Safety Evaluation - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen and Denali’s New Study on LRRK2-Associated Parkinson’s Disease: What Investors Need to Know - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen, Inc. Experiences Valuation Adjustment Amidst Market Performance Challenges - Markets Mojo

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Pregnancy Exposure Study: Implications for MS Treatment Market - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Zuranolone Study: A Potential Game-Changer for Postpartum Depression Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Omaveloxolone Study: Assessing Safety During Pregnancy and Lactation - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s New MS Study: A Potential Game-Changer for Investors? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Omaveloxolone Study: A Closer Look at Long-Term Safety for Friedreich’s Ataxia - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow - Morningstar

Oct 27, 2025
pulisher
Oct 27, 2025

Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer’s Disease - Cantech Letter

Oct 27, 2025
pulisher
Oct 27, 2025

Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer's Disease - Newswire Canada

Oct 27, 2025
pulisher
Oct 27, 2025

AustralianSuper Pty Ltd Has $92.86 Million Stake in Biogen Inc. $BIIB - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

OVERSEA CHINESE BANKING Corp Ltd Cuts Stock Position in Biogen Inc. $BIIB - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

Using portfolio simulators with Biogen Inc. includedMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com

Oct 27, 2025

Biogen Inc (BIIB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general SNY
$50.68
price down icon 0.74%
drug_manufacturers_general PFE
$24.29
price down icon 0.86%
$118.50
price up icon 0.53%
$291.77
price down icon 0.11%
drug_manufacturers_general NVO
$51.37
price down icon 1.31%
drug_manufacturers_general MRK
$86.58
price down icon 0.52%
자본화:     |  볼륨(24시간):